Rhucin, a recombinant C1 inhibitor for the treatment of hereditary angioedema and cerebral ischemia.
Pharming NV and Esteve are developing Rhucin, a recombinant human C1 esterase inhibitor. Rhucin is currently undergoing phase III clinical trials in North America and is awaiting regulatory approval in Western Europe for the treatment of prophylactic and acute hereditary angioedema. Pharming is also investigating Rhucin for the potential treatment of cerebral ischemic injury.
Longhurst
Hilary
H
Barts and The London NHS Trust, Department of Immunology, 80 Newark Street, London E1 2ES, UK. hilary.longhurst@bartsandthelondon.nhs.uk
D000799:Angioedema / Q000188:drug therapy* / Q000235:genetics; D000818:Animals; D002545:Brain Ischemia / Q000188:drug therapy* / Q000235:genetics; D002986:Clinical Trials as Topic; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D017326:Clinical Trials, Phase III as Topic; D050718:Complement C1 Inhibitor Protein / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D006801:Humans; D010330:Patents as Topic; D011994:Recombinant Proteins / Q000627:therapeutic use; D013329:Structure-Activity Relationship
D050718:Complement C1 Inhibitor Protein; D011994:Recombinant Proteins